pali WKN: A4098S ISIN: US6963894026 Forum: Aktien User: Robo1976

👀

Palisade Bio (Nasdaq: PALI) announced a strategic equity investment of up to $500,000 from the Crohn’s & Colitis Foundation through its IBD Ventures program to support development of PALI-2108, a gut-microbiota-activated PDE4 inhibitor designed for targeted delivery to the terminal ileum and colon for fibrostenotic Crohn’s disease (FSCD) and moderate to severe ulcerative colitis (UC). Palisade has completed Phase 1a single- and multiple-ascending dose and food-effect studies, plus a Phase 1b cohort in UC, and is conducting a Phase 1b cohort in FSCD. Data from these studies are expected to support Phase 2 IND submissions to the FDA in 2026.

Läuft gut an🙂

$PALI Form SCHEDULE 13G PALISADE BIO, INC. Filed by: Point72 Asset Management, L.P. Steve Cohen

In its Phase 1a trial, PALI-2108 showed no serious adverse events, lab or ECG abnormalities. The last UC cohort is now being dosed.

🥁

😁🎈

Ui🙂

Palisade Bio Receives Health Canada Clearance for Phase 1b Trial of PALI-2108 in Fibrostenotic Crohn's Disease

Palisade Bio Reports 100% Clinical Response in Phase 1b Ulcerative Colitis Cohort with Novel PDE4 Inhibitor, PALI-2108

👀👀👀